AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16442905 — intervention group
Group type: EXPERIMENTAL
Intervention: No coronary artery disease, second or greater episode of AF, left ventricular ejection fraction < 0.50, and mitral valve thickening (in patients not taking antiarrhythmic drug therapy)
Number of subjects: 1293
Study 16442905 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial diameter > 4.5 cm and mitral valve thickening (in patients taking antiarrhythmic medication)
Number of subjects: 1293
Study 15546536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (mobile phone text messages and reminders sent 2 days per week for 4 months)
Number of subjects: 104
Study 15546536 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual physician interventions)
Number of subjects: 104
Study 15546536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 104
Study 15546536 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 11208863 — intervention group
Group type: EXPERIMENTAL
Intervention: Immature dendritic cells (DCs) pulsed with influenza matrix peptide (MP) and keyhole limpet hemocyanin (KLH)
Number of subjects: 2
Study 9294465 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial chest irradiation (ICI)
Number of subjects: 199
Study 9294465 — intervention group
Group type: EXPERIMENTAL
Intervention: Late chest irradiation (LCI)
Number of subjects: 199
Study 9294465 — intervention group
Group type: COMPARATOR
Intervention: Initial chest irradiation (ICI) with PCI
Number of subjects: 199
Study 9294465 — intervention group
Group type: COMPARATOR
Intervention: Late chest irradiation (LCI) with PCI
Number of subjects: 199
Study 8323383 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg daily for 12 months)
Number of subjects: 19
Study 8323383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3547300 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopherol (adjusted to plasma levels of 3 to 3.5 mg/dL)
Number of subjects: 287
Study 3547300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 31829172 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 stage three larvae of the human hookworm Necator americanus
Number of subjects: 54
Study 31829172 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 stage three larvae of the human hookworm Necator americanus
Number of subjects: 54
Study 31829172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 29879395 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care + brief education (two 30-min education sessions)
Number of subjects: 31
Study 29879395 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 31
Study 26846221 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling
Number of subjects: 63
Study 26846221 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice
Number of subjects: 63
Study 26846221 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (modeling and mental practice)
Number of subjects: 63
Study 26846221 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study 24759870 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Emotion Regulation program (PER program)
Number of subjects: 113
Study 24759870 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation training program
Number of subjects: 113
Study 24759870 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 113
Study 23067920 — intervention group
Group type: COMPARATOR
Intervention: Once daily aspirin (150 mg in the morning)
Number of subjects: 92
Study 23067920 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily aspirin (75 mg in the morning and 75 mg in the evening)
Number of subjects: 92
Study 20052721 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour infusion of paclitaxel at a dose of 250 mg/m² iv every 21 days
Number of subjects: 214
Study 20052721 — intervention group
Group type: EXPERIMENTAL
Intervention: 96-hour infusion of paclitaxel at a dose of 140 mg/m² iv every 21 days
Number of subjects: 214
Study 18568731 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral STN-DBS
Number of subjects: 15
Study 18568731 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamotomy
Number of subjects: 15
Study 18568731 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral subthalamotomy plus contralateral STN-DBS
Number of subjects: 15
Study 18568731 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral stimulation and lesion
Number of subjects: 15
Study 18568731 — intervention group
Group type: EXPERIMENTAL
Intervention: All procedures
Number of subjects: 15
Study 18568731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation and stimulation
Number of subjects: 15
Study 15163133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-mediated intervention based on self-determination theory
Number of subjects: 126
Study 15163133 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving an American Heart Association physical-activity facts packet
Number of subjects: 126
Study 11469917 — intervention group
Group type: EXPERIMENTAL
Intervention: Live instrumental music
Number of subjects: 19
Study 11469917 — intervention group
Group type: EXPERIMENTAL
Intervention: Live vocal music
Number of subjects: 19
Study 11469917 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 19
Study 9725480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 50% drug in core and 180 mg HPMC in coat
Number of subjects: 0
Study 9725480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 67% drug in core and 180 mg HPMC in coat
Number of subjects: 0
Study 9725480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets containing 80% drug in core and 180 mg HPMC in coat
Number of subjects: 0
Study 9725480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets with whole dose in core
Number of subjects: 0
Study 9725480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets with doubled amount of HPMC in coat
Number of subjects: 0
Study 8040738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sedation (INS) with 0.5% midazolam
Number of subjects: 42
Study 8040738 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with midazolam via a pump
Number of subjects: 42
Study 8040738 — intervention group
Group type: COMPARATOR
Intervention: Bolus intravenous sedation (BIVS) with 1 mg midazolam as needed
Number of subjects: 42
Study 2723101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline-containing cross-linked collagen film (TC film)
Number of subjects: 11
Study 2723101 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline-free placebo film
Number of subjects: 11
Study 769489 — intervention group
Group type: EXPERIMENTAL
Intervention: +ECIB
Number of subjects: 101
Study 31559463 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute ACL reconstruction (ACLR) within 8 days of injury
Number of subjects: 70
Study 31559463 — intervention group
Group type: COMPARATOR
Intervention: Delayed ACL reconstruction (ACLR) after normalized range of motion (ROM), 6-10 weeks after injury
Number of subjects: 70
Study 31559463 — intervention group
Group type: EXPERIMENTAL
Intervention: Both acute and delayed ACLR groups
Number of subjects: 70
Study 31559463 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute ACLR
Number of subjects: 70
Study 31559463 — intervention group
Group type: COMPARATOR
Intervention: Delayed ACLR
Number of subjects: 70
Study 31559463 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 31074876 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogic reading intervention
Number of subjects: 32
Study 31074876 — intervention group
Group type: COMPARATOR
Intervention: Screen-exposed intervention
Number of subjects: 32
Study 28987658 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma injection
Number of subjects: 43
Study 28987658 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose-derived stromal vascular fraction injection
Number of subjects: 43
Study 26492467 — intervention group
Group type: EXPERIMENTAL
Intervention: Gordon's Functional Health Pattern Model nursing care and routine care
Number of subjects: 68
Study 26492467 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 68
Study 23468185 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychological intervention plus usual care
Number of subjects: 58
Study 23468185 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study 21487089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (atorvastatin 80 mg)
Number of subjects: 911
Study 21487089 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (pravastatin 40 mg)
Number of subjects: 911
Study 18811568 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally tubeless PCNL (no nephrostomy tube and internal stent)
Number of subjects: 60
Study 18811568 — intervention group
Group type: COMPARATOR
Intervention: Standard PCNL (using nephrostomy tube and ureteral stent)
Number of subjects: 60
Study 16831187 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair
Number of subjects: 40
Study 16831187 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing of defective margins
Number of subjects: 40
Study 16831187 — intervention group
Group type: EXPERIMENTAL
Intervention: Resurfacing
Number of subjects: 40
Study 16831187 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement
Number of subjects: 40
Study 16831187 — intervention group
Group type: COMPARATOR
Intervention: No-treatment
Number of subjects: 40
Study 12510818 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-impact exercise with calcium supplementation (434 ± 19 mg/day)
Number of subjects: 66
Study 12510818 — intervention group
Group type: COMPARATOR
Intervention: Moderate-impact exercise without calcium supplementation
Number of subjects: 66
Study 12510818 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplementation (434 ± 19 mg/day) without exercise
Number of subjects: 66
Study 12510818 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-impact exercise with calcium supplementation
Number of subjects: 66
Study 12510818 — intervention group
Group type: COMPARATOR
Intervention: Low-impact exercise without calcium supplementation
Number of subjects: 66
Study 11777287 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (100,000 IU/day)
Number of subjects: 49
Study 9446265 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice-a-day (TID) gentamicin
Number of subjects: 49
Study 9446265 — intervention group
Group type: COMPARATOR
Intervention: Once-a-day (OD) gentamicin
Number of subjects: 49
Study 9446265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TID and OD gentamicin
Number of subjects: 49
Study 8498939 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 112
Study 8498939 — intervention group
Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 112
Study 3780897 — intervention group
Group type: EXPERIMENTAL
Intervention: FET in a sitting position following a night of horizontal sleep
Number of subjects: 8
Study 3780897 — intervention group
Group type: EXPERIMENTAL
Intervention: FET in a postural drainage position following sleep including postural drainage
Number of subjects: 8
Study 3780897 — intervention group
Group type: COMPARATOR
Intervention: FET with PD during treatment sessions
Number of subjects: 8
Study 29315686 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementation with l-carnitine, acetyl-l-carnitine and other micronutrients for 6 months
Number of subjects: 104
Study 26282343 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (STG) for 16 weeks
Number of subjects: 23
Study 26282343 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 23
Study 24127338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat milkshake high in saturated fatty acids (SFA)
Number of subjects: 0
Study 24127338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat milkshake high in monounsaturated fatty acids (MUFA)
Number of subjects: 0
Study 24127338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat milkshake high in omega 3 polyunsaturated fatty acids (n-3 PUFA)
Number of subjects: 0
Study 21862189 — intervention group
Group type: EXPERIMENTAL
Intervention: 5° lateral wedges
Number of subjects: 73
Study 20018320 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection at a concentration of 10 U/ml to 3 locations around the ureteral orifice
Number of subjects: 51
Study 20018320 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injection
Number of subjects: 51
Study 20018320 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 51
Study 20018320 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 18075758 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (n = 48)
Number of subjects: 97
Study 18075758 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (n = 49)
Number of subjects: 97
Study 16015265 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and Nutrition Education programme
Number of subjects: 541
Study 16015265 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 541
Study 15259473 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (8 mg/kg for 3 days)
Number of subjects: 474
Study 15259473 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg/kg for 3 days)
Number of subjects: 474
Study 15259473 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate and Chloroquine concomitantly (both for 3 days)
Number of subjects: 474
Study 15259473 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate and Chloroquine in sequence (both for 3 days)
Number of subjects: 474
Study 15259473 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine monotherapy
Number of subjects: 474
Study 10576117 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention programme
Number of subjects: 0
Study 10576117 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not participate in the programme)
Number of subjects: 0
Study 8560661 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact laser prostatectomy
Number of subjects: 152
Study 8560661 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 152
Study 8560661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (laser therapy and TURP)
Number of subjects: 152
Study 2065828 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk infant assessed with knowledge of high-risk history
Number of subjects: 2
Study 2065828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk infant assessed with knowledge of low-risk history
Number of subjects: 2
Study 2065828 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk infant assessed with knowledge of high-risk history
Number of subjects: 2
Study 2065828 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk infant assessed with knowledge of low-risk history
Number of subjects: 2
Study 2931346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 472
Study 2931346 — intervention group
Group type: COMPARATOR
Intervention: Spectinomycin
Number of subjects: 472
Study 31170715 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 56
Study 31170715 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 30057053 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain massage (mechanical massage and binaural beats)
Number of subjects: 25
Study 30057053 — intervention group
Group type: COMPARATOR
Intervention: Control (rest or mechanical massage only)
Number of subjects: 25
Study 27184486 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib and dexamethasone (VD)
Number of subjects: 80
Study 27184486 — intervention group
Group type: COMPARATOR
Intervention: Vincristine, adriamycin and dexamethasone (VAD)
Number of subjects: 80
Study 25031315 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline tartrate plus quitline-counseling (VT+C)
Number of subjects: 392
Study 25031315 — intervention group
Group type: COMPARATOR
Intervention: Quitline-counseling alone
Number of subjects: 392
Study 23045536 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 862
Study 23045536 — intervention group
Group type: COMPARATOR
Intervention: Control (no Patient Navigation)
Number of subjects: 862
Study 19680234 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra high-catechin GT3 (886 mg catechins, 198 mg caffeine/day)
Number of subjects: 182
Study 19680234 — intervention group
Group type: EXPERIMENTAL
Intervention: High-catechin GT2 (468 mg catechins, 126 mg caffeine/day)
Number of subjects: 182
Study 19680234 — intervention group
Group type: EXPERIMENTAL
Intervention: High-catechin GT1 (458 mg catechins, 104 mg caffeine/day)
Number of subjects: 182
Study 19680234 — intervention group
Group type: COMPARATOR
Intervention: Control drink (30 mg catechins, 10 mg caffeine/day)
Number of subjects: 182
Study 18931242 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% 2-chloroprocaine followed by 0.5% bupivacaine (C/B)
Number of subjects: 30
Study 18931242 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine followed by 0.5% bupivacaine (L/B)
Number of subjects: 30
Study 17433897 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for venous thrombosis including age, surgery, hospitalization, immobility, trauma, pregnancy, hormone use, cancer, obesity, and hypercoagulation disorders.
Number of subjects: 0
Study 15078003 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP/SMZ)
Number of subjects: 80
Study 15078003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephadroxil
Number of subjects: 80
Study 15078003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil
Number of subjects: 80
Study 10928462 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol, 150 microg levonorgestrel
Number of subjects: 28
Study 10928462 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol, 150 microg desogestrel
Number of subjects: 28
Study 10928462 — intervention group
Group type: COMPARATOR
Intervention: Both OC types
Number of subjects: 28
Study 10928462 — intervention group
Group type: COMPARATOR
Intervention: Antibody against factor XI
Number of subjects: 28
Study 9496216 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. thiopentone combined with i.m. lignocaine (3.0 mg kg‐1)
Number of subjects: 90
Study 9496216 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. thiopentone combined with i.m. bupivacaine (1.0 mg kg‐1)
Number of subjects: 90
Study 9496216 — intervention group
Group type: COMPARATOR
Intervention: i.v. thiopentone alone
Number of subjects: 90
Study 8513523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 32
Study 8513523 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 32
Study 3529971 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol 0.5% twice daily
Number of subjects: 18
Study 3529971 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol 0.5% plus dipivefrin 0.1% twice daily given ten minutes apart
Number of subjects: 18
Study 3529971 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol 0.5% plus dipivefrin 0.1% given twice daily four hours apart
Number of subjects: 18
Study 31007047 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current stimulation plus exercise
Number of subjects: 84
Study 31007047 — intervention group
Group type: COMPARATOR
Intervention: Supervised therapeutic exercise only (control)
Number of subjects: 84
Study 27898496 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine + Naloxone (BUP)
Number of subjects: 795
Study 27898496 — intervention group
Group type: COMPARATOR
Intervention: Methadone (MET)
Number of subjects: 795
Study 25377214 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (peg transfer)
Number of subjects: 36
Study 25377214 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (peg transfer and clipping)
Number of subjects: 36
Study 25377214 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (peg transfer, clipping, and cutting)
Number of subjects: 36
Study 23591634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower lumbar spine Z scores
Number of subjects: 331
Study 23591634 — intervention group
Group type: EXPERIMENTAL
Intervention: BMD at lumbar spine, total hip, and femoral neck
Number of subjects: 331
Study 23591634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein, interleukin 6, receptor activator of nuclear factor κB ligand
Number of subjects: 331
Study 21673183 — intervention group
Group type: EXPERIMENTAL
Intervention: PE-formula (3.1 ± 0.3 g protein/kg/24 h, 119 ± 25 kcal/kg/24 h)
Number of subjects: 18
Study 21673183 — intervention group
Group type: COMPARATOR
Intervention: S-formula (1.7 ± 0.2 g protein/kg/24 h, 84 ± 15 kcal/kg/24 h)
Number of subjects: 18
Study 21673183 — intervention group
Group type: EXPERIMENTAL
Intervention: PE-formula
Number of subjects: 18
Study 21673183 — intervention group
Group type: COMPARATOR
Intervention: S-formula
Number of subjects: 18
Study 19922880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg (1 tablet) alone
Number of subjects: 32
Study 19922880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg (1 tablet) plus probucol 500 mg (2 tablets)
Number of subjects: 32
Study 19922880 — intervention group
Group type: COMPARATOR
Intervention: Probucol 250 mg (1 tablet) alone
Number of subjects: 32
Study 19922880 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol 250 mg (1 tablet) plus cilostazol 100 mg (1 tablet)
Number of subjects: 32
Study 17070169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus warfarin
Number of subjects: 1000
Study 17070169 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 1000
Study 17070169 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus ximelagatran
Number of subjects: 1000
Study 17070169 — intervention group
Group type: COMPARATOR
Intervention: Ximelagatran alone
Number of subjects: 1000